|
Name |
Spinulosin
|
Molecular Formula | C8H8O5 | |
IUPAC Name* |
2,5-dihydroxy-3-methoxy-6-methylcyclohexa-2,5-diene-1,4-dione
|
|
SMILES |
CC1=C(C(=O)C(=C(C1=O)O)OC)O
|
|
InChI |
InChI=1S/C8H8O5/c1-3-4(9)6(11)8(13-2)7(12)5(3)10/h9,12H,1-2H3
|
|
InChIKey |
GFAZBXKENDSJEB-UHFFFAOYSA-N
|
|
Synonyms |
Spinulosin; 85-23-4; 17WG1DAS77; 2,5-dihydroxy-3-methoxy-6-methylcyclohexa-2,5-diene-1,4-dione; 3,6-dihydroxy-5-methoxy-p-toluquinone; 3,6-dihydroxy-4-methoxy-2,5-toluquinone; 2,5-Cyclohexadiene-1,4-dione, 2,5-dihydroxy-3-methoxy-6-methyl-; UNII-17WG1DAS77; HYDROXYFUMIGATIN; SPINULOSIN [MI]; SCHEMBL33978; DTXSID80879392; ZINC1848641; Q27251944; 2,5-Dihydroxy-3-methoxy-6-methylbenzo-1,4-quinone #; 3-METHYL-6-METHOXY-2,5-DIHYDROXY-1,4-BENZOQUINONE; 2,5-Dihydroxy-3-methoxy-6-methyl-2,5-cyclohexadiene-1,4-dione
|
|
CAS | 85-23-4 | |
PubChem CID | 66556 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 184.15 | ALogp: | 0.3 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 13 | QED Weighted: | 0.588 |
Caco-2 Permeability: | -4.801 | MDCK Permeability: | 0.00020781 |
Pgp-inhibitor: | 0.019 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.035 |
Blood-Brain-Barrier Penetration (BBB): | 0.397 | Plasma Protein Binding (PPB): | 82.21% |
Volume Distribution (VD): | 0.416 | Fu: | 10.10% |
CYP1A2-inhibitor: | 0.218 | CYP1A2-substrate: | 0.771 |
CYP2C19-inhibitor: | 0.122 | CYP2C19-substrate: | 0.081 |
CYP2C9-inhibitor: | 0.121 | CYP2C9-substrate: | 0.417 |
CYP2D6-inhibitor: | 0.269 | CYP2D6-substrate: | 0.111 |
CYP3A4-inhibitor: | 0.01 | CYP3A4-substrate: | 0.112 |
Clearance (CL): | 1.435 | Half-life (T1/2): | 0.294 |
hERG Blockers: | 0.006 | Human Hepatotoxicity (H-HT): | 0.623 |
Drug-inuced Liver Injury (DILI): | 0.702 | AMES Toxicity: | 0.068 |
Rat Oral Acute Toxicity: | 0.648 | Maximum Recommended Daily Dose: | 0.007 |
Skin Sensitization: | 0.721 | Carcinogencity: | 0.009 |
Eye Corrosion: | 0.113 | Eye Irritation: | 0.959 |
Respiratory Toxicity: | 0.947 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003525 | 0.886 | D0MM8N | 0.286 | ||||
ENC002293 | 0.488 | D0B9EJ | 0.263 | ||||
ENC001362 | 0.465 | D0Y0GH | 0.225 | ||||
ENC000116 | 0.400 | D03GET | 0.211 | ||||
ENC003505 | 0.391 | D0WY9N | 0.210 | ||||
ENC002456 | 0.362 | D07MGA | 0.205 | ||||
ENC006089 | 0.354 | D0N0OU | 0.204 | ||||
ENC005551 | 0.354 | D06GCK | 0.200 | ||||
ENC005156 | 0.344 | D0G4KG | 0.194 | ||||
ENC002785 | 0.333 | D09WKB | 0.192 |